

#### **Open Access**

**International Journal of Clinical Case Reports and Reviews** 

Gurwant Kaur \*

Case Report

# Acute Kidney Injury in a Case of Multiorgan Failure, **Disseminated Intravascular Coagulation and Purpura Fulminans**

Yan Leyfman<sup>1</sup>, Annie Tsay<sup>1</sup>, Ali Zebi, MD<sup>2</sup>, Salim Baghli<sup>3</sup> MD, Gurwant Kaur, MD, FASN<sup>4</sup>

<sup>1</sup>Penn State College of Medicine, Hershey, PA<sup>,</sup> Penn State Milton S. Hershey Medical Center, Hershey, PA.

<sup>2</sup>Nephrology Fellow, Penn State Milton S. Hershey Medical Center, Hershey, PA.

<sup>3</sup>Department of Medicine in Division of Nephrology, Penn State Milton S. Hershey Medical Center, Hershey, PA.

<sup>4</sup>Assistant Professor, Penn State Milton S. Hershey Medical Center, Hershey, PA.

\* Correspondence Author: Gurwant Kaur, Assistant Professor, Penn State Milton S. Hershey Medical Center, Hershey, PA. Email: gkaur1@pennstatehealth.psu.edu

## Received date: October 29, 2020; Accepted date: December 29, 2020; Published date: January 08, 2021

Citation: Y Leyfman, A Tsay, A Zebi, S Baghli, Kaur. (2021) Acute Kidney Injury in a Case of Multiorgan Failure, Disseminated Intravascular Coagulation and Purpura Fulminans. International Journal of Clinical Case Reports and Reviews. 6(2); DOI:10.31579/2690-4861/088

Copyright: © 2021 Gurwant Kaur, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Introduction: Purpura fulminans (PF) is a life-threatening syndrome consisting of Disseminated Intravascular Coagulation (DIC), thrombotic occlusion of small- and medium-sized blood vessels with skin necrosis. Although there are few studies in the literature, only a minority of them discuss renal manifestations.

Case Report: We present a case of a 57-year-old Caucasian female with acute kidney injury (AKI) in the setting of multiorgan failure (MOF), DIC and PF. She presented with fever, exudative drainage from her port site, and skin changes concerning for bacteremia. Empiric antibiotics were started after blood, urine, and wound cultures were obtained. None of the cultures grew any organisms. Fever resolved after port removal. She exhibited thrombocytopenia, leukopenia, and neutropenia. Urinalysis showed hyaline casts and a fractional excretion of urea (FeUrea) <35% indicating a pre-renal state. Her hospital course was complicated by atrial fibrillation, acute hypoxic respiratory failure requiring mechanical ventilation, and hypovolemic shock requiring pressor support. Further, complicated by multiorgan failure including nonoliguric AKI and heart failure with reduced ejection fraction (HFrEF) of <65%. Acute skin findings included dusky, purple macules and patches involving all digits of both hands as well as gangrenous changes on the face and toes. It prompted further investigation by Hematology and Dermatology. Skin biopsy showed early leukocytoclastic vasculitis changes. Her laboratory markers were suggestive of DIC and Purpura Fulminans.

Keywords: purpura fulminans; multiorgan failure; acute kidney injury; dic

#### Introduction

Purpura fulminans (PF) is a rare and life-threatening syndrome. This was first described by Octave Guelliot in 1884. This presents as intravascular thrombosis and hemorrhagic infarction of the skin and soft tissue that rapidly progresses to multiorgan failure [1]. PF manifests as either a hereditary or acquired deficiency of Proteins C (PROC gene mutation) or S (PROS1 gene mutation). This results in a pro-coagulable state leading to thrombotic occlusion of small and medium-sized blood vessels and manifests as Disseminated Intravascular Coagulation (DIC) and [2-4]. Protein S deficiencies are also caused by liver disease [5].

Although the presentation can vary, patients present with erythematous purpuric macules with blue-black hemorrhagic necrosis typically along the peripheral portions of the skin [5]. Thrombosis of the small vessels leads to hemorrhagic cutaneous necrosis, hypotension, DIC and purpura [1, 6]. Prolonged thrombosis of the small and medium-sized blood vessels will result in full-thickness skin and soft-tissue necrosis of the deeper tissues with MOF of lungs, kidneys, central nervous system, and adrenal glands [7, 8]. This possesses a high mortality rate of close to 50% with most survivors requiring an amputation of the affected extremities [9, 10].

Auctores Publishing - Volume 6(2)-088 www.auctoresonline.org ISSN: 2690-4861

PF can be seen in the setting of sepsis, DIC, or malignancy. There is scarcity of studies on PF in the literature. However, there are few observed cases that can document the extent of this condition in relation to kidney injury. Herein, we present a case of 57-year-old female who exhibited kidney injury in the context of this condition.

## **Case Report**

A 57-year-old Caucasian female was referred to the Emergency Department by her family physician for concerns of a Mediport infection. She experienced fevers, chills, nausea, and vomiting over the course of 24 hours. Her Mediport was placed 6 days prior to presentation for relapsed vs. residual acute myeloid leukemia (AML). The port was draining purulent material.

Her past medical history included hypertension, a hip fracture requiring total hip replacement and hypercalcemia. She was diagnosed with AML in May 2018. She received a fully matched living related allogenic stem cell transplant (SCT) from her sister in August 2018. Her induction therapy included Fludarabine/Busulfan (Flu/Bu2) followed by methotrexate and Neupogen. Her post- SCT course was complicated by

non-oliguric acute kidney injury (AKI) and hepatic graft-versus-host disease (GVHD). Her baseline serum Creatinine (Cr) prior to SCT was 0.6 mg/dL and it trended to a maximum of 3.2 mg/dL. AKI was pre-renal in nature due to poor oral intake and was treated with conservative management. Her current immunosuppression included Prednisone and Tacrolimus. Family history is not significant for cancers, bleeding disorders or kidney disease.

#### **Hospital Course**

She presented with fever of 37.9°C, heart rate of 64 beats per minute, and 20 breaths per minutes. Her blood pressure was 153/75 mmHg. On physical exam, she was breathing comfortably on room air. She had minimal dried yellow-green drainage around her port site. The overlying skin was erythematous and tender to palpation. All other physical examinations were unremarkable. Her laboratory data is outlined in Table 1. Chest X-ray was unremarkable. Patient was started on empiric intravenous antibiotics (Piperacillin-Tazobactam and Vancomycin) for concerns of a port infection. Trimethoprim-Sulfamethoxazole (TMP-

SMX), Acyclovir, and Posaconazole were started as prophylaxis coverage. Blood, urine, and wound cultures remained negative. She had initial resolution of fevers after Mediport removal. Later, she began to have confusion along with intermittent fevers. Magnetic resonance imaging (MRI) of brain and lumbar puncture were unremarkable as well. However, she continued to have recurring and persistent fevers; she was diagnosed with influenza B and was started on oseltamivir.

On hospital day 36, she became hypoxic with new oxygen requirement and new onset atrial fibrillation (AF) with rapid ventricular rate (RVR). She needed end tracheal intubation with pressor support. Nephrology was consulted for non-oliguric AKI with an up trending serum Cr of 1.55 mg/dL (baseline Cr as 0.9 mg/dL) as shown in Figure 1. During her intensive care unit (ICU) stay, she was noted to have necrotic nodule as shown in Figure 2a. The surrounding area had dusky macules and patches involving bilateral hand digits Figure 2b). Differential diagnoses included angioinvasive fungal infection, DIC, or Antineutrophil cytoplasmic antibodies (ANCA) related vasculitis. Also, she had notable gangrenous changes on her nose, fingers, and toes.




Figure 1: Creatinine Curve. This shows the patient's creatinine trend since admission



Figure 2: Dermatologic Findings. (A)- Purpura on Right forearm (B) - Gangrenous digits on Right hand

She continued to have worsening of serum Cr reaching 2.6 mg/dL, and her serum lactate was 9.2mmol/L. Renal replacement therapy (RRT) was not initiated given goals of care discussion with her family. The patient eventually passed away despite implementing life saving measures to prevent DIC in the setting of PF and DIC.

#### Pathogenesis

There are five different subtypes of PF.

1. The most common form is acute or severe sepsis caused by gram negative organisms, including Neisseria meningitidis, Streptococcus pneumonia and Hemophilus influenza [3, 11]. Asplenic patients are at an increased risk [12]

2. The idiopathic or autoimmune form presents with autoantibodies against protein C or S after infections like chicken pox.

3. The acquired form is due to a depletion or decreased synthesis of protein C typically in the presence of vitamin K antagonists, severe liver failure, or complications of prematurity.

4. The congenital form is an autosomal dominant condition with a loss of function due to mutations in protein C, protein S, or antithrombin 3.

5. This subtype is a combination of sepsis and congenital defects that occurs due to mutations in Protein C [13].

Endo- and exotoxins released by gram negative organisms activate tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin 2 (IL-2). This results in the consumption of proteins C and S [14, 15]. A deficiency in proteins C and S results in a pro-coagulable state and contributes to the thrombosis of small and medium sized blood vessels.

#### **Discussion:**

On presentation, she had thrombocytopenia, leukopenia with neutropenia, mild hypokalemia, and elevated liver enzymes. Her urinalysis showed hyaline casts and fractional excretion of urea (FeUrea) was  $\leq$ 35% (Table 1). A transtoracic echocardiogram (TTE) showed a reduced left

ventricular ejection fraction (LVEF) of 45%. A repeat TTE two weeks later showed mildly improved LVEF 50% and new findings of right ventricular (RV) dilation. CT thorax revealed right upper lobe ground glass opacities suggestive of inflammatory or infectious process. A bronchoalveolar lavage (BAL) was negative for bacteria, aspergillosis, nocardia, legionella, anaerobes, and acid-fast bacilli. Cytomegalovirus was negative. A coagulation panel on Day 36 (Table 1) demonstrated elevated D-dimer. PT. PTT. INR. and fibrinogen with thrombocytopenia- a presentation aligned with DIC. Protein C and S were low. She had negative serum ANCA, cryoglobulin, and cryofibrinogen. Cold Agglutinin was within normal limits, which ruled out an infectious cause (Mycoplasma pneumoniae or other primary atypical pneumonia causing pathogens). Uric acid was elevated, which could support tumor lysis syndrome (TLS) in the setting of AML. Anti-IgG direct antiglobulin test (DAT) and antibody screen were negative for autoimmune hemolytic anemia (Table 2). Skin biopsy showed early leukocytoclastic vasculitis changes. A new necrotic nodule on the patient's right forearm revealed vascular occlusion with negative fungal stains suggestive of PF.

	Admission	Nephrology Consult (Day	Normal Range
	(Day 1)	36)	_
Electrolyte Panel			
Sodium	139	134 (L)	136-145mmol/L
Potassium	3.3	4.0	3.5-5.1mmol/L
Chloride	98	102	98-107mmol/L
Bicarbonate	25	9 (L)	22-29mmol/L
Anion Gap	16	23 (H)	5-14mmol/L
Blood Urea Nitrogen	9	33 (H)	6-23mg/dL
Creatinine	0.89	1.55 (H)	0.60-1.00mg/dL
Estimated Creatinine Clearance	59.17	35.29 (L)	
Estimated Glomerular Filtration Rate	>60	34 (L)	>60ml/min/1.73m <sup>2</sup>
Glucose	128	48 (L)	74-109mg/dL
Calcium	9.3	7.1 (L)	8.4-10.2mg/dL
Magnesium	2.9	2.1	1.6-2.6mg/dL
Ionized Calcium		0.95 (L)	1.15-1.27mmol/L
Phosphorous	2.7	3.6	2.5-4.5mg/dL
White Blood Cell Panel			
White Blood Cell Count	0.32 (PMN <500)	0.85 (L)	4.0-10.4K/ul
Hemoglobin	8.0	9.0 (L)	11.7-15.0g/dL
Hematocrit	23.4	27.0 (L)	35-44%
Red Blood Cell	2.58	3.05 (L)	3.90-5.00M/uL
Mean Corpuscular Volume	90.7	88.5	81-96fL
Mean Corpuscular Hemoglobin Concentration	34.2	33.3	32-36g/dL
Mean Corpuscular Hemoglobin	31.0	29.5	28-33pg
Red Distribution Width	17.3	16.1 (H)	11.5-14.2%
Platelets	122	7 (L)	150-350K/uL
Prothrombin Time	14.1	27.4 (H)	12.0-14.2 s
International Normalized Ratio	1.1	2.4 (H)	0.9-1.1
Partial Thromboplastin Time	30	47 (H)	23-35 s
Haptoglobin	70		
Fibrinogen		748 (H)	208-435mg/dL
Coagulation Panel		· · · ·	· · · · · · · · · · · · · · · · · · ·
D-dimer			<0.54ug/mL

Lactate	1.6	9.2 (H)	0.5-2.2mmol/L	
Alanine Aminotransferase	33	62 (H)	0-33unit/L	
	43	38 (H)	0-32unit/L	
Aspartate Aminotransferase	45	38 (H)	0-32umi/L	
	0.9	2.2 (II)	0.0.1.2 / 11	
Total Bilirubin Direct Bilirubin	0.9	2.2 (H)	0.0-1.2mg/dL	
	104	100 (II)	25.115.14	
Alkaline Phosphatase	124	198 (H)	35-115unit/L	
Albumin	4.6	2.8 (L)	3.5-5.2g/dL	
Protein	7.4	5.4 (L)	6.4-8.3g/dL	
Lactate Dehydrogenase	306	317 (H)	135-250unit/L	
Uric Acid	3.6	5.6	2.7-6.4mg/dL	
Tacrolimus	<2.0			
Lipase		6 (L)	13-60unit/L	
Urine Analysis				
Color	Straw	Yellow		
Appearance	Clear	Slightly Cloudy		
Glucose	Negative	Negative		
Bilirubin	Negative	Negative		
Ketones	Negative	Negative		
Specific Gravity	1.005	1.011	1.005-1.030	
Hemoglobin	Small	Small		
pH	8.0	6.0	5.0-8.0	
Protein	30	100		
Urobilinogen	0.1-1.0	0.1-1.0	0.1-1.0	
Nitrite	Negative	Negative		
Leukocyte Esterase	Negative	Negative		
White Blood Cell		0-4	0-4	
Red Blood Cell		0-4	0-4	
Bacteria		Few		
Squamous Epithelial Cells		Few		
Hyaline Casts		1-4		
Mucous		Few		
Creatinine (U)		15.72		
Sodium (U)		88		
Urea Nitrogen (U)		112		

Table 1: Patient's labs are presented on Day of Admission (Day 1) and Day 36 when Nephrology was consulted

Lab Test	Result	Reference Range		
Hematology Panel				
Protein C	13	70-150%		
Activated Protein C Resistance	10	≥2.00		
Protein C Antigen	15	70-140%		
Protein S, Functional	29	50-120%		
Protein S, Free	81	55-123%		
Fibrinogen	282	208-435mg/dL		
D-Dimer	>20.00	<0.54ug/mL		
Prothrombin Time	30.3	12.0-14.2 s		
International Normalized Ratio	2.8	0.9-1.1		
Partial Thromboplastin Time	71	23-35 s		
Rheumatology Panel				
Anti-Neutrophil Cytoplasmic Antibody	No detectable ANCA antibody			
Screen	NI			
Cryoglobulin	Negative			
Cryofibrinogen	Negative			
Cold Agglutinin	<1:32	<1:32		
Uric Acid	8.2	2.7-6.4 md/dL		
Immune Profile				
Anti-Complement 3 antibody	Negative			
Direct Antiglobulin Test, anti-IgG	Negative			

Table 2: Specialty Labs Performed

In this case, AKI was largely multifactorial. There was no evidence of acute tubular necrosis (ATN) given lack of urinary granular casts or tissue diagnosis/kidney biopsy; but was highly possible in later course with oligoanuria. Her sub-nephrotic range proteinuria was likely tubular in nature as well. A kidney biopsy was not feasible given critical clinical situation of the patient. Hence, it is hard to prove toxic ATN from medications. Also, she was maintained on reasonable vancomycin levels. Multiple factors contributing to AKI in this case included chemotherapy with underlying immunosuppressed status secondary to AML, use of immunomodulators, sepsis/septic shock (culture negative), antibiotics and decreased effective circulating volume in phase of AF with RVR. Septic shock with MOF along with worsening lactic acidosis preceded the worsening of AKI.

PF is a condition with a poor prognosis and high mortality rate of over 40%, where supportive care is the mainstay of treatment [1, 5, 18]. Studies have suggested anticoagulation to halt necrosis, and replacement of blood and blood products (coagulation factors, and platelets) to control DIC progression. In advanced cases, like ours, it is also recommended that patients be given fresh frozen plasma and protein C concentrate to improve survival rates. However, our patient's clinical course was too advanced to halt disease progression[13, 19]. Early surgical debridement of necrotic areas has been shown to decrease mortality [20, 21].

#### Conclusion

This case demonstrates the importance of early diagnosis and intervention in advanced life-threatening conditions, like PF, due to its rapid course and poor clinical outcome.

#### **Conflict of Interest**

The authors declare that they have no competing interests.

#### **Author's Contributions**

YL was responsible for reviewing the literature, summarizing and organizing the data, and writing the Abstract, Introduction, and Discussion of the manuscript. AT was responsible for gathering the data, summarizing the patient's clinical course, organizing the data, contributing to the Discussion, and writing the case presentation of the manuscript.

AZ and SB were responsible for editing the discussion.

GK was responsible for reviewing and editing the entire manuscript multiple times. GK also provided critical thinking and finalized the manuscript. All authors read and approved the final manuscript.

#### References

- 1. Nolan J, Sinclair R. (2001) Review of management of purpura fulminans and two case reports. Br J Anaesth. 86(4):581-586.
- 2. Dominey A, Kettler A, Yiannias J, Tschen JA. (1988) Purpura Fulminans and Transient Protein C and S Deficiency. Archives of Dermatology. 124(9):1442-1443.
- Mukherjee D, Pal P, Kundu R. (2015) Purpura Fulminans Due to Acquired Protein C Deficiency. Indian J Dermatol. 60(6):637.
- Wypasek E, Undas A. (2013) Protein C and protein S deficiency - practical diagnostic issues. Adv Clin Exp Med. 22(4):459-467.

- Edlich RF, Cross CL, Dahlstrom JJ, Long WB. (2008) 3<sup>rd</sup> Modern concepts of the diagnosis and treatment of purpura fulminans. J Environ Pathol Toxicol Oncol. 27(3):191-196.
- Darmstadt GL. (1998) Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 15(3):169-183.
- Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, et al. (2011) Purpura fulminans: recognition, diagnosis and management. Arch Dis Child. 96(11):1066-1071.
- Shenoy R, Nanjappa S, Eaton K, Prieto-Granada C, Messina JL, Greene JN. (2017) Purpura Fulminans: A Case Report and Review of All Causes. Infectious Diseases in Clinical Practice. 25(2):100-104.
- 9. Childers BJ, Cobanov B. (2003) Acute infectious purpura fulminans: a 15-year retrospective review of 28 consecutive cases. Am Surg. 69(1):86-90.
- 10. Betrosian AP, Berlet T, Agarwal B. (2006) Purpura fulminans in sepsis. Am J Med Sci. 332(6):339-345.
- Shah A, Lettieri CJ. (2008) Fulminant meningococcal sepsis in a woman with previously unknown hyposplenism. Medscape J Med. 10(2):36.
- 12. Ward KM, Celebi JT, Gmyrek R, Grossman ME. (2002) Acute infectious purpura fulminans associated with asplenism or hyposplenism. J Am Acad Dermatol. 47(4):493-496.
- 13. Perera TB, Murphy-Lavoie HM. (2020) Purpura Fulminans. StatPearls. Treasure Island (FL): StatPearls Publishing, StatPearls Publishing LLC.
- 14. Ramachandran G. (2014) Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 5(1):213-218.
- 15. Surbatovic M, Popovic N, Vojvodic D, Milosevic I, Acimovic G, Stojicic M, et al. (2015) Cytokine profile in severe Grampositive and Gram-negative abdominal sepsis. Sci Rep.
- 16. Barbar SD, Binquet C, Monchi M, Bruyere R, Quenot JP. (2014) Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomized controlled trial. Trials.
- Schiffl H, Lang SM, Fischer R. (2002) Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 346(5):305-310.
- Bandyopadhyay D, Panchabhai TS, Choudhary C. (2015) Presence of rash in a catastrophic condition. J Emerg Trauma Shock. 8(3):170-171.
- Knoebl P, Schellongowski P, Staudinger T, Sperr WR, Scheibenpflug C. (2013) Treatment Of Infection-Associated Purpura Fulminans With Protein C Zymogen Is Associated With a High Survival Rate. Blood.122(21).
- 20. Roughton MC, Agarwal S, Gottlieb LJ. (2011) Surgical management of acute infectious purpura fulminans. J Burn Care Res. 32(2):231-236.
- 21. Klifto KM, Gurno CF, Grzelak MJ, Seal SM, Asif M, Hultman CS, et al. (2019) Surgical outcomes in adults with purpura fulminans: a systematic review and patient-level meta-synthesis. Burns Trauma.